You are here

Roche drug cocktail doubles chance of holding lung cancer at bay

Zurich

ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.

Thirty-seven per cent of patients in a closely watched clinical

sentifi.com

Market voices on:

Powered by GET.comGetCom